Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers

British Journal of Clinical Pharmacology

Volumn 65, Issue 4, 2008, Pages 523-530

  Damle, Bharat ^a   LaBadie, Robert ^a   Crownover, Penelope ^a   Glue, Paul ^a  

^a PFIZER INC   (United States)

Author keywords

Efavirenz; Pharmacokinetics; Voriconazole

Indexed keywords

EFAVIRENZ; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIZZINESS; DRUG CROSS REACTIVITY; FATIGUE; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN EXPERIMENT; MENTAL DISEASE; NEUROLOGIC DISEASE; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; STEADY STATE; VASCULAR DISEASE; VISUAL DISORDER;

ADULT; ANTIFUNGAL AGENTS; BENZOXAZINES; BODY WEIGHT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; DRUG INTERACTIONS; EPIDEMIOLOGIC METHODS; HUMANS; MALE; PYRIMIDINES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; TRIAZOLES;

EID: 40549118557     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.03085.x     Document Type: Article

References (19)

1. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002 347 : 408 15.
2. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, Cleary JD, Rubinstein E, Church LW, Brown JM, Schlamm HT, Oborska IT, Hilton F, Hodges MR. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005 366 : 1435 42.
3. Ally R, Schürmann D, Kreisel W, Carosi G, Aguirrebengoa K, Dupont B, Hodges M, Troke P, Romero AJ Esophageal Candidiasis Study Group. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001 33 : 1447 54.
4. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003 31 : 540 7.
5. Sustiva® (efavirenz) prescribing information. Bristol-Myers Squibb Company. Last revised January 2007.
6. Niwa T, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 2005 28 : 1805 8.
7. von Moltke LL, Greenblatt DJ, Granda BW, Giancarlo GM, Duan SX, Daily JP, Harmatz JS, Shader RI. Inhibition of human cytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol 2001 41 : 85 91.
8. Mouly S, Lown KS, Kornhauser D, Joseph JL, Fiske WD, Benedek IH, Watkins PB. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 2002 72 : 1 9.
9. Fellay J, Marzolini C, Decosterd L, Golay KP, Baumann P, Buclin T, Telenti A, Eap CB. Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients. Eur J Clin Pharmacol 2005 60 : 865 73.
10. Smith PF, DiCenzo R, Morse GD. Clinical pharmacokinetics of non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 2001 40 : 893 905.
11. Liu P, Foster G, Labadie R, Allison J, Sharma A. Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy subjects. Clin Pharmacol Ther 2005 2 : P40.
12. Gerzenshtein L, Patel SM, Scarsi KK, Postelnick MJ, Flaherty JP. Breakthrough Candida infections in patients receiving voriconazole. Ann Pharmacother 2005 39 : 1342 5.
13. Kupper LL, Hafner KB. How appropriate are popular sample size formulas? Am Stat 1989 43 : 101 5.
14. Roffey SJ, Cole S, Comby P, Gibson D, Jezequel SG, Nedderman AN, Smith DA, Walker DK, Wood N. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 2003 31 : 731 41.
15. Purkins L, Wood N, Parviz G, Love ER, Eve MD, Fielding A. Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration. Br J Clin Pharmacol 2003 56 : 37 44.
16. Vfend® (voriconazole) prescribing information. Pfizer Inc. Last revised November 2006.
17. Joshi AS, Barrett JS, Fiske WD, Pieniaszek HJ, Ludden TM, Bacheler LT, Ruiz NM. Population pharmacokinetics of efavirenz in Phase II studies and relationship with efficacy. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, Calif., September 1999 [Poster 1201].
18. Ikeda Y, Umemura K, Kondo K, Sekiguchi K, Miyoshi S, Nakashima M. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther 2004 75 : 587 8.
19. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharm 2006 46 : 235 43.